Cytori Therapeutics, Inc.
Daniels E.
Animal Study, published in Regen Med (2007) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Regen Med (2007)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 17511568
- DOI
- 10.2217/17460751.2.3.317
Abstract (original English)
Cytori Therapeutics, Inc. develops stem and regenerative cell therapies that can be used in a 'real-time' treatment setting for cardiovascular disease, reconstructive surgery and many other serious, chronic and life-threatening conditions and disorders. Cytori uses adult stem cells from adipose tissue, which offers a rich, accessible and autologous source of adult stem cells, and maximizes these benefits to create a cost-effective and safe treatment option.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.